These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 25285425)

  • 1. Effect of nanovaccine chemistry on humoral immune response kinetics and maturation.
    Haughney SL; Ross KA; Boggiatto PM; Wannemuehler MJ; Narasimhan B
    Nanoscale; 2014 Nov; 6(22):13770-8. PubMed ID: 25285425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-dose combination nanovaccine induces both rapid and long-lived protection against pneumonic plague.
    Wagner DA; Kelly SM; Petersen AC; Peroutka-Bigus N; Darling RJ; Bellaire BH; Wannemuehler MJ; Narasimhan B
    Acta Biomater; 2019 Dec; 100():326-337. PubMed ID: 31610342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced humoral and mucosal immune responses after intranasal immunization with chimeric multiple antigen peptide of LcrV antigen epitopes of Yersinia pestis coupled to palmitate in mice.
    Uppada SB; Bhat AA; Sah A; Donthamshetty RN
    Vaccine; 2011 Nov; 29(50):9352-60. PubMed ID: 22001881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases.
    Ulery BD; Kumar D; Ramer-Tait AE; Metzger DW; Wannemuehler MJ; Narasimhan B
    PLoS One; 2011 Mar; 6(3):e17642. PubMed ID: 21408610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lung deposition and cellular uptake behavior of pathogen-mimicking nanovaccines in the first 48 hours.
    Ross KA; Haughney SL; Petersen LK; Boggiatto P; Wannemuehler MJ; Narasimhan B
    Adv Healthc Mater; 2014 Jul; 3(7):1071-7. PubMed ID: 24520022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concomitant administration of Yersinia pestis specific monoclonal antibodies with plague vaccine has a detrimental effect on vaccine mediated immunity.
    Eyles JE; Butcher WA; Titball RW; Hill J
    Vaccine; 2007 Oct; 25(42):7301-6. PubMed ID: 17869388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell-mediated immune response and Th/Th cytokine profile of B-T constructs of F1 and V antigen of Yersinia pestis.
    Gupta G; Khan AA; Rao DN
    Scand J Immunol; 2010 Mar; 71(3):186-98. PubMed ID: 20415784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal Protollin/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection.
    Jones T; Adamovicz JJ; Cyr SL; Bolt CR; Bellerose N; Pitt LM; Lowell GH; Burt DS
    Vaccine; 2006 Mar; 24(10):1625-32. PubMed ID: 16243411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inducing systemic and mucosal immune responses to B-T construct of F1 antigen of Yersinia pestis in microsphere delivery.
    Tripathi V; Chitralekha KT; Bakshi AR; Tomar D; Deshmukh RA; Baig MA; Rao DN
    Vaccine; 2006 Apr; 24(16):3279-89. PubMed ID: 16476510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cationic liposome-hyaluronic acid hybrid nanoparticles for intranasal vaccination with subunit antigens.
    Fan Y; Sahdev P; Ochyl LJ; Akerberg J; Moon JJ
    J Control Release; 2015 Jun; 208():121-129. PubMed ID: 25869965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T cells play an essential role in anti-F1 mediated rapid protection against bubonic plague.
    Levy Y; Flashner Y; Tidhar A; Zauberman A; Aftalion M; Lazar S; Gur D; Shafferman A; Mamroud E
    Vaccine; 2011 Sep; 29(40):6866-73. PubMed ID: 21803090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An optimized vaccine vector based on recombinant vesicular stomatitis virus gives high-level, long-term protection against Yersinia pestis challenge.
    Palin A; Chattopadhyay A; Park S; Delmas G; Suresh R; Senina S; Perlin DS; Rose JK
    Vaccine; 2007 Jan; 25(4):741-50. PubMed ID: 16959385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple antigen peptide consisting of B- and T-cell epitopes of F1 antigen of Y. pestis showed enhanced humoral and mucosal immune response in different strains of mice.
    Ali R; Kumar S; Naqvi RA; Sheikh IA; Rao DN
    Int Immunopharmacol; 2013 Jan; 15(1):97-105. PubMed ID: 23174507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetics of memory B cell and plasma cell responses in the mice immunized with plague vaccines.
    Zhang X; Wang Q; Bi Y; Kou Z; Zhou J; Cui Y; Yan Y; Zhou L; Tan Y; Yang H; Du Z; Han Y; Song Y; Zhang P; Zhou D; Yang R; Wang X
    Scand J Immunol; 2014 Mar; 79(3):157-62. PubMed ID: 24383627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of immunological responses of plague vaccines F1+rV270 and EV76 in Chinese-origin rhesus macaque, Macaca mulatta.
    Qiu Y; Liu Y; Qi Z; Wang W; Kou Z; Zhang Q; Liu G; Liu T; Yang Y; Yang X; Xin Y; Li C; Cui B; Huang S; Liu H; Zeng L; Wang Z; Yang R; Wang H; Wang X
    Scand J Immunol; 2010 Nov; 72(5):425-33. PubMed ID: 21039737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell-mediated immune response to epitopic MAP (multiple antigen peptide) construct of LcrV antigen of Yersinia pestis in murine model.
    Shreewastav RK; Ali R; Uppada JB; Rao DN
    Cell Immunol; 2012; 278(1-2):55-62. PubMed ID: 23121976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of a recombinant F1-V fusion protein vaccine intended to protect Canada lynx (Lynx canadensis) from plague.
    Wolfe LL; Shenk TM; Powell B; Rocke TE
    J Wildl Dis; 2011 Oct; 47(4):888-92. PubMed ID: 22102659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple antigen peptide containing B and T cell epitopes of F1 antigen of Yersinia pestis showed enhanced Th1 immune response in murine model.
    Ali R; Naqvi RA; Kumar S; Bhat AA; Rao DN
    Scand J Immunol; 2013 May; 77(5):361-71. PubMed ID: 23480362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electroporation of a multivalent DNA vaccine cocktail elicits a protective immune response against anthrax and plague.
    Albrecht MT; Livingston BD; Pesce JT; Bell MG; Hannaman D; Keane-Myers AM
    Vaccine; 2012 Jul; 30(32):4872-83. PubMed ID: 22633906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving the Th1 cellular efficacy of the lead Yersinia pestis rF1-V subunit vaccine using SA-4-1BBL as a novel adjuvant.
    Dinc G; Pennington JM; Yolcu ES; Lawrenz MB; Shirwan H
    Vaccine; 2014 Sep; 32(39):5035-40. PubMed ID: 25045812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.